Glenmark gets USFDA nod for psoriasis spray

PTI New Delhi | Updated on March 27, 2018 Published on March 27, 2018

Glenmark Pharmaceuticals has received final nod from the US health regulator for its Clobetasol Propionate spray used for the treatment of moderate to severe plaque psoriasis in adults.

Glenmark Pharmaceuticals Inc, USA has received final approval from the United States Food & Drug Administration (USFDA) for Clobetasol Propionate spray 0.05 per cent, the company said in a statement today.

The product is a generic version of Galderma Laboratories L P’s Clobex spray in the same strength. This product will be manufactured at the Glenmark’s Baddi plant in Himachal Pradesh.

“As per IQVIA sales data for the 12-month period ending January 2018, the Clobex spray, 0.05 per cent market that includes brand and all available therapeutic equivalents achieved annual sales of approximately $30.5 million,” it said.

The company’s portfolio consists of 131 products authorised for distribution in the US market and 63 ANDAs pending approval with the USFDA. Glenmark stock was trading 0.12 per cent up at Rs 539.95 on the BSE.

Published on March 27, 2018
This article is closed for comments.
Please Email the Editor